July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Secondary IOL Implantation among aphakic children in the Infant Aphakia Treatment Study
Author Affiliations & Notes
  • Carolyn Drews-Botsch
    Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, United States
  • Azhar Nizam
    Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, United States
  • Edward Wilson
    Medical University of South Carolina, South Carolina, United States
  • Deborah Vanderveen
    Harvard University, Boston, Massachusetts, United States
  • Scott R Lambert
    Ophthalmology, Stanford University, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Carolyn Drews-Botsch, None; Azhar Nizam, None; Edward Wilson, None; Deborah Vanderveen, None; Scott Lambert, None
  • Footnotes
    Support  NH Grant 5UG1 EY013272; NH Grant 5UG1 EY013287, NH Grant 5UG1 EY025553
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3135. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Carolyn Drews-Botsch, Azhar Nizam, Edward Wilson, Deborah Vanderveen, Scott R Lambert; Secondary IOL Implantation among aphakic children in the Infant Aphakia Treatment Study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3135.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Implanting an intraocular lens (IOL) at the time of cataract extraction is not standard of care for infants with unilateral congenital cataract (UCC). This analysis examines secondary IOL implantation between age 5 and 10½ years. We hypothesized that most aphakic patients would elect to have IOL implantation, and implantation would be associated with visual acuity (VA) and adherence to contact lens wear.

Methods : The Infant Aphakia Treatment Study (IATS) is a randomized controlled trial of initial treatment for UCC. Participants randomized to standard treatment were left aphakic until age 5 unless poor adherence to contact lens use threatened vision, and then only with the approval of the IATS Steering Committee. After age 5, secondary IOL implantation was left to the discretion of the surgeon and the family. Secondary IOL implantation was assessed at age 10 1/2 years through medical record review.

Results : 53 children who were randomized to be left aphakic were followed at age 10 ½ years of age; 22 of these (42%) had received a secondary IOL. The Steering Committee approved secondary IOL implantation prior to age 5 in 3 patients (6%), and these are excluded from subsequent analyses. All 9 patients at one site received a secondary IOL; 7 (78%) before 6½. Another received an IOL at 6.6 years. At the remaining sites, 10 of 41 aphakic children (24%) received secondary IOLs; 7 (70%) before age 6½. At sites where secondary IOL implantation was not routine, visual acuity at age 4½ years was not associated with secondary IOL implantation (3 of 12 patients (25%) with visual acuity (VA) better than 20/40; 2 of 10 patients (20%) with VA 20/40 to < 20/200; and 5 of 19 patients (26%) with VA 20/200 or worse) (Fisher’s exact test p=1.0) None of the 5 children who reported wearing a contact lens less than half of waking hours when 4 years of age received a secondary IOL; 31% (8 of 26, Fisher’s Exact test p=0.3) of those reporting more contact lens use received a secondary IOL.

Conclusions : There is variation among centers and families regarding elective secondary IOL implantation for children with a UCC who are initially left aphakic, and neither visual acuity nor adherence to CL wear appear to be driving this choice. Since children who are 5 years of age are in the typical age for IOL implantation, many families chose to proceed soon after they became eligible.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.